DraperDraper is an independent, not-for-profit corporation, which means its primary commitment is to the success of clients’ missions rather than to shareholders. For either government or private sector customers, Draper leverages its deep experience and innovative thinking to be an effective engineering research and development partner, designing solutions or objectively evaluating the ideas or products of others.
Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumour microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.
Xylyx Bio, Inc.
Xylyx Bio is harnessing the power of tissue-specific extracellular matrix, the cell’s native environment, for both cell culture and tissue regeneration applications. By bringing the native in-vivo environment to the in-vitro setting, Xylyx Bio’s tissue-specific ECM substrates support cell culture models that are significantly more predictive of human physiology, thus facilitating acceleration of drug discovery and development. We are committed to providing scientists with biomimetic solutions that transform the way biomedical research is conducted. From the very beginning, cells can be cultured in vitro but still studied in their natural environment – leading to better science and faster translation of results.
For more than 25 years, Corning has delivered innovations designed to advance scientific research in areas like 3D cell culture, drug screening, cancer research, stem cell research, bioprocessing and cell therapy. Corning solutions are used by researchers worldwide to create more in vivolike environments intended to deliver more biologically relevant results. Corning’s product portfolio includes tools like permeable supports, biological and synthetic ECMs, cell culture flasks, filtration systems, reusable glassware, bioprocessing scale-up solutions, assay microplates, and PCR products.
CELLINK was the first bioink company in the world and is today’s leading provider of 3D bioprinters. We design and commercialize bioprinting technologies – enabling researchers to 3D print organs and tissue for applications that span industries, from pharmaceutical to cosmetic. Founded in 2016, CELLINK is now changing the future of medicine in hundreds of labs across more than 50 countries.